Versant Ventures VII GP, L.P.
CIK: 0001777655
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (100.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LYCA
Lycia Therapeutics, Inc.
10% Owner
Discretionary Trading P&L
Holdings
About Versant Ventures VII GP, L.P.
Versant Ventures VII GP, L.P. (SEC CIK 0001777655) files insider reports with the SEC as 10% Owner of Lycia Therapeutics, Inc. (LYCA).
Signal8 holds 2 ownership filings by Versant Ventures VII GP, L.P. (1 Form 3, 1 Form 4), filed between Oct 22, 2026 and Oct 28, 2026. Those filings report 2 transactions, the latest on Oct 26, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Versant Ventures VII GP, L.P.'s filings is in SAN FRANCISCO, CA.
Recent filings by Versant Ventures VII GP, L.P.
- Oct 26, 2026: Conversions of LYCA shares (2 lines, Form 4, code C).
Other insiders filing for Lycia Therapeutics, Inc. (LYCA)
- Venrock Healthcare Capital Partners III, L.P., 10% Owner
- Fischer Laurent, Director
- Henderson Jane, Director
- RIEFLIN WILLIAM JL, Director
- Touami Sofia, Chief Business Officer
- Staben Steven, Chief Scientific Officer